Introduction
About 30% of children and young people with epilepsies do not respond to the first two appropriate antiepileptic drugs (AEDs), and can be considered to have ''intractable'' or ''difficult to treat'' epilepsies. 1, 2 Gabapentin (GAB) is an AED with proven efficacy in treating partial seizures and secondarily generalised seizures. 3 It binds intracellularly to the a2d1-subunit and a2d2-subunit of neuronal voltage-dependant calcium channels, impairing their normal trafficking function, leading to reduced neurotransmitter release. 4 GAB first had marketing authorisation in the USA as an AED in 1994, and in the UK has marketing authorisation for use in children over 6 years of age with difficult to treat epilepsies. However, there are few studies of GAB in children. 5 There are few studies published on its long-term use, tolerability, toxicity, efficacy, and retention. A few clinical trials have been published, but these have had relatively short follow-up periods of 12-24 weeks. 6, 7 We proposed to undertake this retrospective chart review, of all children starting GAB treatment for epilepsies at 3 adjacent paediatric neurology/epilepsy centres in the UK, with outcomes observed beyond 12 months. This study reports on the use of GAB in 105 separate treatment episodes in 105 paediatric patients with difficult to treat epilepsies, at 3 centres over a 14 year period.
Methods
Children under 18 years of age starting treatment with GAB from February 1995 to August 2009 were ascertained retrospectively from hospital pharmacy and paediatric neurology databases in three tertiary referral paediatric neurology departments. GAB was prescribed as adjunctive therapy for controlling difficult to treat focal or generalised epilepsies by the Consultant paediatric neurologists at the tertiary departments. A retrospective chart review using a standard proforma to capture demographic data, aetiology, epilepsy syndrome, seizure frequency, medication dosage, concomitant AEDs, efficacy and adverse events was recorded at more than 2, 6 and 12 months from starting that AED. The proforma was used at all sites to ensure recording consistency. Epilepsies were classified using all available clinical data, by the International League Against Epilepsies' (ILAE) 1988 system. 8 Data was analysed using SPSS 18.0 on an intention to treat basis. As this was not a prospective trial with allocation of treatments, but an observational study of recent local practice, the ''intention to treat'' analysis of perceived efficacy used the complete data set including all patients who had started the AED, including those in whom it had been withdrawn. A few patients were omitted from the perceived efficacy analyses at some time windows if they had not been withdrawn but were not observed during that time window. Statistical methods included simple descriptive statistics, Chisquared for differences in aetiology and seizure type, and KaplanMeier survival plot for time on the AED.
This was an observational non-intervention study. The protocol has been tried and tested, 9 and was registered as a clinical audit by the Nottingham University Hospital's NHS Trust, Sheffield Children's NHS Foundation Trust, and Birmingham Children's Hospital NHS Foundation Trust.
Results
105 treatment episodes in 105 children (55% male) were ascertained. Patients starting GAB ranged from 1.3 to 17.5 years (normal distribution, mean 10.1), including 17 under 6 years of age. The population had mostly early onset of seizures, with a median age of onset of 2.5 years (range 0 months to 14.7 years). GAB was used in epilepsies with a variety of aetiologies and classifications, most commonly in symptomatic focal epilepsies in 46 (44%). In all, 81 (77%) of cases had focal, and 55 (52%) symptomatic epilepsies (Table 1) .
Brain magnetic resonance imaging (MRI) and electroencephalography (EEG) reports were available in 91% and 99% of cases respectively. MRI was abnormal in 53/96 (55%) and EEG was abnormal in 66/104 (63%), with 37/104 (36%) having at least one EEG demonstrating focal epileptiform discharges.
The intractable nature of this study population's epilepsies is demonstrated by the number of previously withdrawn (Table 2) and concomitant AEDs (Table 3 ). Only 4 patients had received GAB as the 1st choice, 25 patients as the 2nd choice, with 76 patients received GAB as 3rd or later choices. 1 patient had been withdrawn from 15 AEDs prior to starting GAB, and 1 patient was on 4 other AEDs in addition to GAB.
This study comprised 157 young person-treatment years for GAB. Mean maximum dosage was 43.7 mg/kg/day (range 6.0-87.3, median 44.2).
16 patients on GAB achieved monotherapy. Of these patients, 1 had Idiopathic Generalised Epilepsy, 8 had Symptomatic Focal Epilepsies, 1 had a Symptomatic Generalised Epilepsy, 2 had Cryptogenic Focal Epilepsies and 4 had Unknown Focal Epilepsies. Of these 16, 10 had a significant improvement (greater than 50% seizure reduction compared to pre-GAB baseline) and 1 was seizure free. For 4 of these patients, GAB was the 1st choice, 4 the 2nd choice, 2 the 3rd choice, 4 the 4th choice, and 2 the 5th choice of AED.
Possibly and probably related adverse events were reported in 39% of GAB treatment episodes. The most frequently reported adverse events being behavioural problems (such as disruption at school and mood swings) in 16 (15%), sleep problems in 9 (8.5%), and weight/appetite changes in 6 (6%). 64 (61%) reported no adverse events attributed to GAB treatment (Table 4) . Most adverse events appeared within the first 3 months of treatment. The adverse events seen were often at the lower-end of the recommended dosage ranges. Most adverse events were mild, and resolved without requiring withdrawal of medication, although GAB was withdrawn from 14 (13%) because of adverse reactions (either alone or with additional lack of efficacy). No serious events were recognised in any of the treatment episodes. No patients died during their period of study observation. 57 (54%) children withdrew from GAB: 10 because of adverse events, 4 due to lack of efficacy and adverse effects, 40 due to perceived lack of efficacy, 2 due to being seizure free, and 1 due to disliking the taste and poor compliance.
Data was available for analysis from 66 treatment episodes at 2 < 6 months, 59 at 6 < 12 months and 58 at over 12 months follow up. 47 children were not followed up beyond 12 months, due to missing data as a result of not attending clinic frequently enough, missing appointments, transfer to adult services, or withdrawal from GAB prior to 12 months.
The retention rate beyond 12 months, of all patients commenced on treatment and assuming those lost to follow up had come off the AED, were 55% (58/105) beyond one year follow up since commencing treatment (Fig. 1) .
Seizure response rates of greater than 50% reduction were reported at 12 months or longer follow-up, with 35% (37/105) of those starting treatment experiencing a benefit, remaining either seizure free (6/105), or experiencing some seizures but with a greater than 50% reduction in seizure frequency (31/105) compared to baseline. At 2 < 6 months follow-up, of those observed 41% (27/66) experienced an improvement, and at 6 < 12 months follow-up, of those observed 34% (20/59) experienced an improvement compared to baseline. Patients achieving an initially good response tended to maintain a reduction in seizure frequency.
Discussion
Gabapentin in this retrospective pragmatic observational study has been shown to be effective and well tolerated for long term use as an AED in children with intractable epilepsies, as was suggested by previous short term controlled trials in children with secondary generalised and refractory partial seizures. 6, 7, 10 Gabapentin was equally effective against partial seizures in children with and without intellectual disability.
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This study adds to the existing literature by demonstrating the effects of GAB in a defined paediatric cohort, evaluating the effects of GAB on seizure frequency and its tolerability and safety. It shows that the findings of short term controlled trials stand up to the test of time and longer follow-up in ''real'', unselected, patients managed as part of every-day practice, i.e. who are not in a controlled trial. This is important as GAB has a reputation of being relatively ineffective: a view fostered by the modest dose recommendation given in the original Summary of Product Characteristics, which was up to about half the doses used commonly now, and the preferential marketing of Pregabalin, which has the same mechanism of action, 12 by the main manufacturer of GAB. It is of interest to note that 3 multi-centre, randomised, double-blind, placebo-controlled trials on patients with refractory partial epilepsy have demonstrated efficacy of Pregabalin as an adjunctive antiepileptic therapy, with 31-51% of patients showing a 50% reduction in seizure frequency, 13 compared to 35% in this observational study. Whilst 39% on GAB reported some adverse effects, there were no serious adverse effects in 157 young person-years of exposure. Behavioural problems such as tantrums, defiance and aggression have also been associated with GAB treatment for epilepsies and other neurological conditions, and typically resolve on dose modification or withdrawal.
14-16 15% of children started on GAB experienced behavioural problems, such as mood swings, negative thoughts and disruption at school. However, some were tolerated by the caregivers and treatment was only withdrawn because of adverse events in 13%. Some children had behavioural and learning difficulties before GAB, so it is difficult to attribute these all to the medication per se, although those with pre-existing problems are more susceptible to exacerbation. 17 Whatever the multi-factorial causes, it is nonetheless important to recognise that deterioration in cognitive function, mood and behavioural adverse effects may well be encountered after starting GAB.
The main limitation of this study is the retrospective nature of the data collection, so it is possible that some adverse events may have been due to concomitant AEDs or other medications, and that some adverse reactions were not recorded in the medical records.
The main strength of this study is the ''reality'' of drug use, in the practical clinical setting where a variety of confounding factors can influence treatment as opposed to the strict control of variables in the randomised control trial setting. Assessing the impact on patient behaviour, mood and cognition would require a prospective study that records objectively changes in behaviour, mood and cognition before attributing change in behaviour and cognition to use of GAB.
Retention was favourable for GAB, with 55% remaining on treatment beyond 12 months since commencing treatment. The results of those continuing treatment throughout the three observation periods of 2 < 6, 6 < 12 and 12+ months since commencing treatment are the most useful measure of how GAB performed in terms of efficacy and tolerability in the paediatric cohort. The results of this study support the findings of tolerability and efficacy of similar studies of children with intractable epilepsies on GAB. 10 Seizure freedom was achieved in 6% started on GAB, 3 of whom had focal epilepsy of unknown aetiology, 1 with symptomatic focal epilepsy, 1 with cryptogenic focal epilepsy and one patient with idiopathic generalised epilepsy. A further 29% started on GAB had a significant reduction (<50% fewer seizures compared to baseline) in seizure frequency beyond 12 months follow up. As this was retrospective, seizure frequency was not always recorded from a diary, but as with normal clinical practice, some indication of seizure frequency and change in frequency as perceived by the caregivers and the prescribing paediatric neurologist was usually recorded even when diary counts were not, e.g. a change from ''several seizures a day'' to ''several a week'' comprised a greater than 50% seizure reduction. When no convincing seizure frequency estimate was available for a visit of a child on GAB, they were excluded from the perceived efficacy analysis. Due to the conservative nature of what was considered an improvement, these results demonstrated that a substantial number of young patients with epilepsies will benefit from treatment with GAB, even with generalised epilepsies.
The methods used in this study are comparable to those used in other studies of newer AEDs including Levetiracetam, Zonisamide, Topiramate, Lamotrigine and Clobazam 9, 18, 19 so the results may be compared to the performance of those drugs in the paediatric population. [ ( F i g . _ 1 ) T D $ F I G ] Fig. 1 . Discontinuation of Gabapentin over 365 days.
GAB comes in a capsule formulation and is usually given in three daily doses. 20 Other AEDs have a simpler once or twice daily regimen and may come in dispersible or syrup formulation. GAB has a bitter taste and many children find swallowing tablets and capsules difficult. 21 One patient found the taste particularly unpalatable and discontinued as a consequence, however all other patients tolerated the taste if they could swallow the capsule. Physicians may be avoiding GAB due to its formulation in favour of medicines with a more favourable formulation, especially in younger children. Our study confirms the efficacy, tolerability and safety profile of GAB in a paediatric cohort with intractable epilepsies. The multicentre nature of this study improves the generalisability of the data to paediatric cohorts with intractable epilepsies. Multicentre prospective studies would be required to demonstrate the longer-term efficacy and the impact GAB will have on behaviour, mood and cognitive function of children.
Conclusions
This study confirms the efficacy and safety profile of GAB in young people with intractable epilepsies.
